Multifaceted Management of Primary Hyperoxaluria

Primary hyperoxaluria encompasses a group of rare autosomal recessive disorders in which defective hepatic enzymes lead to overproduction of oxalate, resulting in recurrent nephrolithiasis, nephrocalcinosis and progressive renal impairment. Management has evolved from general measures—vigorous hydration, crystallisation inhibitors such as citrate and dietary oxalate restriction—to genotype-guided interventions including pyridoxine in responsive variants of alanine:glyoxylate aminotransferase deficiency. Recent advances integrate molecular therapies and personalised approaches: RNA interference agents targeting hepatic lactate dehydrogenase or glycolate oxidase have shown promising reductions in urinary and plasma oxalate across genetic subtypes. Adjunctive strategies under investigation include small-molecule modulators of oxalate transport, microbiome-based oxalate degradation and epigenetic regulators of inflammatory pathways. In patients with established kidney failure, combined liver–kidney transplantation remains the definitive cure, although sequential or isolated renal transplantation is explored in pyridoxine-sensitive cases. A multidisciplinary framework unites nephrology, hepatology, genetics and urology to tailor interventions according to disease type, renal function and patient age. Globally, the integration of novel therapies offers the prospect of reducing the burden of end-stage renal disease and systemic oxalosis, with implications for resource-limited settings where access to transplantation is constrained. Ongoing studies aim to define long-term outcomes, optimise dosing regimens and elucidate the role of emerging biomarkers in treatment monitoring.

Research from Nature Portfolio

Recent studies have demonstrated that modulation of inflammatory pathways can mitigate oxalate-induced renal injury. In an experimental model of hyperoxaluria, oral acetate therapy reduced macrophage infiltration and renal fibrosis by enhancing histone acetylation in tubular cells and upregulating a microRNA that suppresses macrophage migration inhibitory factor. These findings reveal an epigenetic mechanism for protecting renal tissue and suggest acetate or related compounds as potential adjunctive treatments to limit crystal-induced inflammation and preserve kidney function.

Multifaceted Management of Primary Hyperoxaluria publication trend

The graph below shows the total number of articles in multifaceted management of primary hyperoxaluria across all publications each year (not limited to Nature Index journals).

Technical terms

Primary hyperoxaluria: A group of inherited disorders characterised by hepatic overproduction of oxalate leading to kidney stones and renal failure.

Oxalate: An end-product of glyoxylate metabolism that precipitates as calcium oxalate crystals in the urinary tract.

Nephrolithiasis: The formation of kidney stones within the renal system.

Nephrocalcinosis: Deposition of calcium salts in renal parenchyma, often associated with crystal nephropathies.

RNA interference: A process in which small interfering RNA molecules silence specific genes by promoting degradation of their messenger RNA.

Pyridoxine: A form of vitamin B6 that serves as a cofactor to enhance enzymatic activity in certain metabolic disorders.

Alanine:glyoxylate aminotransferase (AGT): The liver peroxisomal enzyme deficient in primary hyperoxaluria type 1.

References

1. Acetate attenuates hyperoxaluria-induced kidney injury by inhibiting macrophage infiltration via the miR-493-3p/MIF axis. Communications Biology (2023).
2. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney International (2021).
3. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney International (2022).
4. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children. Genetics in Medicine (2021).
5. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis (2017).
6. Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatric Nephrology (2021).